Scottish Parliamentary Exchange on the Assessment of Ultra-Orphan Treatments – Answered 25th April 2017
Miles Briggs, Lothian, Scottish Conservative and Unionist Party:
To ask the Scottish Government what progress it is making in implementing the new assessment process for ultra-orphan treatments, which was recommended by the Review of Access to New Medicines.
Answered by Shona Robison:
Dr Montgomery’s independent review on access to new medicines recognised that the Scottish Government has made significant reforms and investment to improve access to newly licensed medicines in recent years.
I announced in December that we will be taking forward the recommendations from the review. We are collaborating with a range of clinical experts, patient groups and other stakeholders to take forward, as quickly as possible, implementation of the new assessment and approval pathway for ultra-orphan medicines recommended by the review.
We continue to build on the improvements made by our previous reforms but we require drug manufacturers to make reforms too, so they bring forward medicines at a fair price.
Where a medicine is not accepted by the SMC for routine use in Scotland, NHS Boards do have systems in place where clinicians can request access to these medicines on an individual patient case by case basis.